Fed. Circ. Won't Rehear Partial Ax Of Horizon Arthritis Drug IP
A divided Federal Circuit on Tuesday declined to revisit a ruling that struck down parts of Horizon's patents for its arthritis drug Pennsaid, drawing a dissent from four judges arguing that...To view the full article, register now.
Already a subscriber? Click here to view full article